Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Analysts and Calls -- Sterling Research -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1)	10/17/2002 11:50:24 AM
From: Icebrg	Read Replies (1) \| Respond to of 5

Immucor Demands Correction of Sterling Research Report 08-12-02 10:42 AM EST \| Immucor, Inc. (Nasdaq: BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, refuted today an August 8, 2002 research report by Sterling Research, a division of Sterling Financial Investment Group. Edward L. Gallup, President and Chief Executive Officer of Immucor, said, "This is a very serious misunderstanding of the facts. Immucor believes Sterling's August 8 research report is based almost entirely on serious factual inaccuracies concerning Olympus, an instrument manufacturer that uses Immucor's FDA-licensed reagents on its PK7200 automated blood donor instrument. The Sterling report concludes that a significant amount of Immucor's revenues are exposed to potential erosion because Olympus controls a major portion of the North American blood-testing market and is getting ready to sell its own reagents in competition with Immucor. In fact, Olympus operates in an important but relatively small part of Immucor's overall blood- testing market, and the FDA-licensed reagents Olympus intends to use on its instrument have been developed and manufactured by Immucor's wholly-owned subsidiary, Gamma Biologicals, Inc." Mr. Gallup added, "Reagent sales for the Olympus instrument are not material to Immucor's operations." Immucor has demanded that Sterling immediately correct all inaccuracies in the report. Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of our market segments. That almost looks like another of Mr Risk's assignments. Ice